FDA Tentatively Approves Dr. Reddy’s Generic HIV Prevention Shot, Expanding Access

The U.S. Food and Drug Administration has granted tentative approval to Dr. Reddy’s Laboratories for a generic version of a groundbreaking HIV prevention medicine. This decision marks a significant step toward making pre-exposure prophylaxis (PrEP) more affordable and accessible in the United States and globally. The move could lower costs and increase supply, addressing a critical gap in HIV prevention efforts, especially in underserved communities. While tentative approval means the product cannot yet be marketed due to existing patents or exclusivities, it signals readiness for future launch. The announcement comes amid broader industry activity, including Lonza’s acquisition of U.S. manufacturing facilities, highlighting a trend of expanding production capacity for essential medicines. As HIV prevention remains a public health priority, this development could accelerate progress toward ending the epidemic by improving access to effective prevention tools. The next step will be final approval once patent barriers are resolved.